Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Type of publications
Guidelines (30)
NITAG documentation (1591)
Reports (55)
SAGE documentation (218)
Scientific publications (112)
Systematic reviews (SYSVAC) (2750)
Regions
Africa (267)
Americas (762)
Eastern Mediterranean (48)
Europe (704)
South-East Asia (78)
Western Pacific (196)
Diseases
Chikungunya (9)
Cholera (33)
COVID-19 (1481)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
4756 results found
2018
∙
Demicheli, V. Jefferson, T. Ferroni, E. Rivetti, A. Di Pietrantonj, C.
Vaccines for preventing influenza in healthy adults
2018
∙
Jefferson, T. Rivetti, A. Di Pietrantonj, C. Demicheli, V.
Vaccines for preventing influenza in healthy children
2018
∙
Demicheli, V. Jefferson, T. Di Pietrantonj, C. Ferroni, E. Thorning, S. Thomas, R. E. Rivetti, A.
Vaccines for preventing influenza in the elderly
2018
∙
Odey, F. Okomo, U. Oyo‐Ita, A.
Vaccines for preventing invasive salmonella infections in people with sickle cell disease
2018
∙
Milligan, R. Paul, M. Richardson, M. Neuberger, A.
Vaccines for preventing typhoid fever
2018
∙
SAGE
Meeting of the Strategic Advisory Group of Experts on Immunization, October 2018 – Conclusions and recommendations
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seronegative individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
What is the efficacy of 3 doses of CYD-TDV in preventing clinical dengue in seropositive individuals 9-16 years of age in the first year following vaccination?
2018
∙
SAGE
Should countries considering introduction of CYD-TDV to reduce the burden of dengue use a pre-vaccination screening or population seroprevalence based criteria?
2018
∙
SAGE
Should CYD-TDV be recommended, over no vaccination, to immunocompetent individuals (≥9 years of age) in dengueendemic countries to mitigate the dengue burden of disease?
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register